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Abstract
Low-molecular mimetic BDNF GSB-106, which is a substituted dimeric dipep-
tide, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, was designed 
and synthesized in the V. V. Zakusov Research Institute of Pharmacology. The 
dipeptide activates TrkB, PI3K/AKT, and MAPK/ ERK. GSB-106 is being developed 
as a potential antidepressant. Its antidepressant activity was detected in a number of 
rodent tests (0.1–1.0 mg/kg, ip; 0.5–5.0 mg/kg, po). In the present study, GSB-106 
was shown to completely eliminate the manifestation of anhedonia in the sucrose 
preference test and to increase disturbed hippocampal synaptogenesis at acute oral 
administration (0.1 mg/kg) after 10-day social defeat stress in C57Bl/6 mice.
Keywords: BDNF, depression, dipeptide mimetic GSB-106, anhedonia, 
synaptogenesis, synaptophysin
1. Introduction
Depression is one of the most widespread mental disorders leading to social dis-
adaptation. According to the WHO data in 2012, there were more than 350 million 
people suffering from depression. Modern antidepressants require long-term use 
to achieve a therapeutic effect, while their effectiveness does not exceed 60% [1]. 
Therefore, the creation of antidepressants with new action mechanisms is regarded 
as one of the most pressing pharmacology problems.
Fundamental studies established that the pathogenesis of depression was associ-
ated with impaired neuroplasticity in the hippocampus and the prefrontal cortex, 
caused by deficit of brain-derived neurotrophic factor (BDNF) [2]. The clinical 
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evidence demonstrates that BDNF levels in blood plasma decrease in depression and 
resolve as the result of antidepressant therapy [3]. A reduced BDNF content in the 
prefrontal cortex and hippocampus was found in suicide victims [4]. The antide-
pressant properties of BDNF were investigated based on its physiological functions. 
The antidepressant effect of neurotrophin was revealed after central administra-
tion in different depression models in rodents [5]. Antidepressant activity was also 
experimentally established for BDNF mimetic 7,8-dihydroxyflavone, an antagonist 
of BDNF-specific TrkB receptors [6].
Following the discovery of antidepressant properties of ketamine, over the 
past decade, a lot of efforts have been made to create new antidepressants with a 
glutamatergic mechanism of action without ketamine-like side effects. To date, 
one of them, rapastinel, a modulator of NMDA receptors, is in a third phase of 
clinical trials [7]. From the theoretical point of view, the most important fact is that 
antidepressant effect of ketamine and other glutamatergic drugs is mediated by 
activation of BDNF-TrkB-Akt-mTORC1-signaling cascade which leads to enhanced 
synaptogenesis [8]. The data proving that mTOR inhibition leads to the disappear-
ance of ketamine antidepressant effects serve as pharmacological confirmation of 
this conclusion [8].
Thus, both pathophysiological evidence and results of experimental and clinical 
pharmacological studies demonstrate the feasibility of using the BDNF-TrkB recep-
tor system as a pharmacological target of search for new antidepressants.
A mimetic of the fourth loop of BDNF, GSB-106, which is a substituted 
dimeric dipeptide, bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenedi-
amide, was designed and synthesized in the V. V. Zakusov Research Institute 
of Pharmacology [9]. GSB-106 was established to activate BDNF-specific TrkB 
receptors and their main post-receptor signaling pathways—PI3K/AKT and 
MAPK/ERK [10]. GSB-106 demonstrated antidepressant activity at intraperito-
neal (i.p.) (0.1–1.0 mg/kg) and oral (0.5–5.0 mg/kg) administration in a number 
of rodent tests [11, 12]. GSB-106 was also shown to stimulate neurogenesis and 
synaptogenesis in mouse hippocampus [13, 14].
A tablet dosage form of GSB-106 for oral administration was developed in 
the Technological Department of the Institute (application for a patent of the 
Russian Federation 2018107362 from 28 02 2018) to create a drug on the basis of 
the substance. The dosage form of GSB-106 was shown to be active at doses of 
0.01–5.0 mg/kg in forced swimming test in mice and to exceed the “gold standard” 
of antidepressants, amitriptyline, by intensity of effects [11].
The aim of the current study was to investigate antidepressant effects of the 
tablet dosage form of GSB-106 at acute administration in a model of depression-like 
state in mice caused by social defeat stress, in comparison with the widely used anti-
depressant amitriptyline, having affinity to TrkB receptors according to some data 
[15]. This model is considered to be one of the most appropriate, since it reproduces 
the main behavioral and neurobiological signs of depression [16].
2. Materials and methods
2.1 Drugs
GSB-106 (bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenediamide) was 
synthesized in the Department of Medicinal Chemistry of the V. V. Zakusov Research 
Institute of Pharmacology, as described previously [9]. The tablet dosage form 
of GSB-106 was developed in the Technological Department of the V. V. Zakusov 
Research Institute of Pharmacology, аs described (application for a patent of the 
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Russian Federation 2018107362 from 28 02 2018). The form contained 1% of GSB-
106 and 99% of filler, consisting of lactose, microcrystalline cellulose, polyethylene 
glycol-polyvinyl alcohol copolymer, and magnesium stearate. The tablet dosage 
form of amitriptyline was purchased from Federal State Unitary Enterprise “Moscow 
Endocrine Plant” (Russia).
2.2 Animals
Male adult C57BL/6 mice weighing 18–20 g and male adult outbred mice weigh-
ing 25–28 g were used in the study. The animals were obtained from the “Stolbovaya” 
Central Laboratory for Animal Breeding (Moscow Region, Russia). The animals were 
housed in a vivarium with a natural change of light regime and free access to stan-
dard pelleted food and water. The study was carried out in accordance with the Order 
of the Ministry of Health Care and Social Development of the Russian Federation 
No. 199n of 01 04 2016 “Approval Rules of Good Laboratory Practice” and with the 
Resolution of the Eurasian Economic Commission No. 81 “Concerning adoption of 
the Good laboratory practice of EAEU in the field of drug circulation.” All manipu-
lations with the animals were approved by the Institutional Animal Care and Use 
Committee of the V. V. Zakusov Research Institute of Pharmacology (Moscow).
2.3 Social defeat procedure
A depressive-like state in C57BL/6 mice was created by chronic stress caused by 
repeated experiences of social defeats in daily confrontations between males. The 
social defeat stress was performed as previously reported [6]. The outbred male 
mice were used as aggressors. The C57BL/6 mice and outbred mice were placed 
in pairs into experimental cages (28 × 14 × 10 sm), divided in half by a perforated 
Plexiglas wall, one mouse per compartment. The animals were held in sensory con-
tact in the absence of direct physical interaction for 2 days. Separator was removed 
for 10 min on day 3 to allow animals opportunity for direct contact. Under these 
conditions, the larger outbred mouse acted as an “aggressor.” The confrontation 
was stopped before the expiration of 10 min in the case of overly aggressive attacks 
by the outbred mouse (the bites continued even after the victim mouse had dem-
onstrated a submissive pose). C57BL/6 mice were given daily stress for 10 days as 
described above, which leads to the development of a depressive-like state, accord-
ing to the literature [16].
2.4 Design of the experiment
After 10 days of social defeat stress, the social avoidance test was conducted on 
day 11 to select mice with depressive-like behavior. Then these mice were randomly 
divided into three groups of eight animals each:
The control (stress) group
The “stress + GSB-106” group
The “stress + amitriptyline” group
2.5 Mice were placed into individual cages
On day 12, mice of the “stress + GSB-106” group were orally administered with 
GSB-106 in the dosage form at a dose of 0.1 mg/kg (for the active substance), 
suspended in 1% starch solution; the “stress” group was administered orally with 
1% starch solution; the group of “stress + amitriptyline” was administered orally 
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amitriptyline in the tablet form at a dose of 10 mg/kg, suspended in 1% starch solu-
tion. Three more groups of mice (eight animals per group) not subjected to stress 
were formed simultaneously with the beginning of social stress modeling. On day 
11, these groups were single orally administered with a 1% starch solution (control 
group [no stress]), GSB-106 (the group “GSB-106 [without stress]”) or amitripty-
line (group “amitriptyline [without stress]”) in a 1% starch solution, respectively. 
The dose of GSB-106 was selected based on previously conducted experiments [12]; 
the one of amitriptyline was based on literature data [17]. The sucrose preference 
test was performed on day 13. Mice were decapitated; the hippocampus was isolated 
for subsequent evaluation of the synaptogenesis intensity on day 16. The scheme of 
the experiment is shown in Figure 1.
2.6 The social avoidance test
This test was performed to select mice that developed depressive-like behavior 
as the result of social defeat stress, as described in [6]. The infrared actimeter from 
Panlab (Spain) with ActiTrack software (field size 40.0 × 44.0 cm) was used. An 
individual transparent plastic chamber with holes (8.0 × 8.0 × 8.0 cm) was placed 
at one end of the field of the actimeter. A mouse was placed into the actimeter for 
2.5 min. Then the mouse was returned to the home cage for 30 s. At this time, the 
“aggressor” unknown for the testing mouse was placed in the plastic chamber, and 
the testing mouse was placed in the actimeter for 2.5 min again. The duration of the 
mouse presence in the “interaction zone” (at a distance of 8.0 cm or less from the 
camera with the aggressor) was estimated. The interaction ratio (IR) was calculated 
as the ratio of the time spent in the interaction zone in the presence of the aggressor 
to the time spent in the interaction zone without the aggressor. The value IR < 1 was 
defined as a criterion for depressive-like behavior. Only the mice showing depres-
sive-like behavior in this test (about 90% of the animals) were used in the further 
experiment.
2.7 The sucrose preference test
Mice were exposed to bottles with water and 1% sucrose solution. The consump-
tion of water and sucrose solution was evaluated by weighing the bottles. The 
preference of the sucrose solution was calculated by the following formula:
A(s)/(A(s) + A(w)) × 100%, where A(s) is the amount of consumed sucrose 
solution, g, and W(w) is the amount of consumed water, g. The reduction of this 
parameter below the control group level was regarded as the development of stress-
induced anhedonia [6]. The test was carried out for 18 h.
2.8 Evaluation of hippocampal synaptogenesis
The content of the presynaptic marker synaptophysin in hippocampus was 
assessed using Western blot analysis. After defrost, the hippocampal tissue samples 
were homogenized at 4°C in a glass homogenizer with lysis buffer (50 mM Tris-
HCl, 5 mM EDTA, 1 mM dithiothreitol, 1% Triton X-100, pH 7.5) supplemented 
with a protease inhibitor cocktail (pepstatin, bestatin, leupeptin, and aprotinin, 
“Sigma-Aldrich,” USA), in the ratio of tissue: buffer = 1:10 (weight/volume). 
Then the samples were incubated at 4°C for 20 min and centrifuged at 15,000 rpm 
(Allegra® X-12R centrifuge “Beckman Coulter Inc.,” USA) at the same temperature 
for 20 min. The protein levels of the supernatant lysates were determined by the 
method of Folin-Lowry. The supernatant proteins were separated in a 12% poly-
acrylamide gel and then transferred onto a polyvinylidene fluoride membrane by 
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electroelution. The membranes were deactivated with 5% (w/v) nonfat dry milk 
in Tris buffer containing 1% Tween 20 (TBST) for 1 h. Then, the membranes were 
treated with primary monoclonal mouse antibodies against synaptophysin (“BD 
Biosciences,” United Kingdom) at a dilution of 1:5000 for 1.5 h, the antibody excess 
was washed with TBST with 0.5% (w/v) nonfat dry milk, and the membranes 
were incubated at 37°C with goat antibodies against rabbit IgG (“Santa Cruz 
Biotechnology,” USA, 1:1000), conjugated with horseradish peroxidase, for 1 h. The 
detection of proteins was performed after washing the secondary antibodies with 
TBST buffer in the reaction with enhanced chemiluminescence substrates (ECL 
reagents, Santa Cruz Biotechnology) using the Alliance Q9 gel documenting system 
(UVITEC, United Kingdom). Densitometry of the obtained images was performed 
using the GIMP2 program.
2.9 Statistical analysis
The intergroup differences were assessed using one-way analysis of variance 
ANOVA, followed by post hoc Fisher’s LSD test or the Mann-Whitney U test. 
Differences were considered statistically significant at p ≤ 0.05; the value of p < 0.1 
was regarded as a tendency. The data were presented as mean and standard errors of 
the mean.
3. Results and discussions
One of the main behavioral signs of depression is anhedonia. Anhedonia is 
a violation of the brain “reward system,” it is considered as a key symptom of 
depression both in the International Classification of Diseases of the tenth revision 
(ICD-10) and in the Classification of Mental Disorders of the American Psychiatric 
Association’s Diagnostic and Statistical Manual (DSM-5). A common method for 
assessing anhedonia in animals is the sucrose preference test [6].
In our study the sucrose preference was statistically significantly reduced 
in the stressed mice (the “control [stress]” group) compared with the intact 
animals (the “control [without stress]” group) (Table 1). GSB-106 statistically 
and reliably restored the preference of the sucrose solution to the control level. 
Amitriptyline also restored the preference of the sucrose solution. However, the 
administration of GSB-106 or amitriptyline to intact animals did not affect the 
results of this test (Table 1).
Figure 1. 
The scheme of the experiment.
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Figure 2. 
The synaptophysin level in the hippocampus of mice on the fourth day after the administration of GSB-106 
or amitriptyline. Data are presented as mean ± SEM. Bands: 1, control (without stress); 2, GSB-106 (without 
stress); 3, amitriptyline (without stress); 4, control (stress); 5, “stress + GSB-106”; 6, “stress + amitriptyline.” 
Note: *p < 0.05 compared with the placebo group; #p = 0.08 compared with the stress group (Mann-Whitney  
U test).








the 1% sucrose 
solution, %
Control (without stress) 8 11.4 ± 1.2 2.73 ± 0.5 80.7 ± 3.2
GSB-106 (0.1 mg/kg) 
(without stress)
8 10.08 ± 0.8 2.14 ± 0.3 82.4 ± 2.8
Amitriptyline (10.0 mg/kg) 
(without stress)
8 10.02 ± 0.7 3.47 ± 0.1 74.3 ± 6.5
Control (stress) 8 6.67 ± 0.5 2.12 ± 0.2 75.9 ± 2.4*
Stress + GSB-106 (0.1 mg/kg) 8 10.9 ± 1.1 2.4 ± 0.3 81.9 ± 3.1#
Stress + amitriptyline 
(10.0 mg/kg)
8 13.7 ± 0.9 2.5 ± 0.4 84.8 ± 3.6#
Data are presented as mean ± SEM.
*p < 0.05 comparison with the “control (without stress)” group.
#p < 0.05 comparison with the “control (stress)” group (ANOVA followed by the use of the Fisher’s LSD method).
Table 1. 
The preference of 1% sucrose solution in С57Bl/6 male mice subjected to 10 days of stress, 1 day at acute oral 
administration of GSB-106 or amitriptyline (test duration—18 h).
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Thus, dipeptide mimetics BDNF GSB-106 completely eliminated the mani-
festations of anhedonia at acute administration in mice subjected to 10-day social 
defeat stress.
GSB-106 was previously shown [13] to enhance the synaptophysin content in 
the hippocampus of mice at chronic administration (21 days). In this study, GSB-
106 also caused a statistically significant increase of the synaptophysin content in 
the hippocampus of the control animals after acute administration (Figure 2). In 
stressed animals, synaptophysin content in the hippocampus was reduced by 30% 
compared with nonstressed ones. Such a decrease can be considered as a charac-
teristic sign of a depressive-like state, since the hippocampus is the structure most 
susceptible to pathological changes during depression, as well as the prefrontal 
cortex, and synaptogenesis impairment is considered as one of the main patho-
physiological signs of this disease [2]. The pronounced tendency to restore the level 
of synaptophysin was observed (p = 0.08) at administration of both GSB-106 and 
amitriptyline to the stressed animals (Figure 2).
4. Conclusions
The dipeptide mimetic BDNF GSB-106, like amitriptyline, exhibits anti-anhedo-
nia activity after acute oral administration after 10 days of social defeat stress. The 
effect of GSB-106 was manifested in doses 100 times smaller than amitriptyline, the 
drug of comparison.
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